Data Program Tytuł
mar 2024

Exploring novel lipid nanoparticle compositions for effective delivery of mRNA - Posters

Ewelina Juszczyk, Karolina Fedko, Paweł Żero, Katarzyna Filip, Michał Mroczkiewicz, Mateusz Mach, Beata Zygmunt, Marta Mikońska, Joanna Hucz-Kalitowska, Małgorzata Choroś, Emilia Mróz, Maciej Wieczorek - publication

mar 2024 Inflammatory diseases / PI3K

Development and optimization of a continuous flow ester reduction with LiAlH4 in the synthesis of a key intermediate for a PI3Kδ inhibitor (CPL302415) - Publications

Stanisław Michałek, Anna M. Maj, Lidia Gurba-Bryśkiewicz, Wioleta Maruszak, Marcin Zagozda, Zbigniew Ochal, Krzysztof Dubiela and Maciej Wieczorek - publication

sty 2024 Diabetes / GPR40

First-in-human study of CPL207280, a novel G-protein-coupled receptor 40/free fatty acid receptor 1 agonist, in healthy volunteers after single and multiple administration - Publications

Katarzyna Bazydło-Guzenda PhD, Katarzyna Jarus-Dziedzic PhD, Agnieszka Gierczak-Pachulska PhD, Paweł Buda PhD, Piotr J. Rudzki DSc, Katarzyna Buś-Kwaśnik PhD, Ewelina Juszczyk PhD, Ewa Tratkiewicz MSc, Daniel Rabczenko PhD, Agnieszka Segiet-Święcicka PhD, Maciej Wieczorek PhD - publication

paź 2023 Oncology

CPL976, an innovative bispecific antibody targeting AXL and PD-L1 axis as a potential new anticancer therapeutic - Publications

Agnieszka Bojko-Matuszek, Damian Kołakowski, Magdalena Bojko, Aleksandra Sowińska, Filip Mituła, Krzysztof Lacek, Delfina Popiel, Sebastian Kwiatkowski, Tomasz Kornatowski, Beata Kliszcz, Anna Jabłońska, Krzysztof Flis, Bartosz Wiernicki, Maciej Wieczorek , Jerzy Pieczykolan, Olga Abramczyk - poster

paź 2023 Oncology

Design and preclinical evaluation of CPL976-MMAE - novel, potent AXL-PD-L1 bispecific antibody conjugated with MMAE in targeted anticancer therapy - Publications

Delfina Popiel, Krzysztof Lacek, Anna Jabłońska, Aleksandra Sowińska, Agnieszka Bojko – Matuszek Damian Kołakowski, Filip Mituła, Sebastian Kwiatkowski, Magdalena Bojko, Tomasz Kornatowski, Beata Kliszcz, Tomasz Banach, Michał Górka, Jerzy Pieczykolan, Maciej Wieczorek, Olga Abramczyk - poster

paź 2023 Neuropsychiatry / PDE10A

Repeated, 4-week dosing of CPL’36, a novel PDE10A inhibitor, does not induce tolerance to its antipsychotic-like action - Publications

J. Krzemień, A. Nikiforuk, N. Malikowska-Racia, A. Potasiewicz, J. Gołębiowska, E. Cyrano, K. Skowrońska, K. Górski, S. Kokhanovska, M. Wieczorek1, P. Popik, M. Matłoka - poster

paź 2023

`Quality by Design (QbD) and Design of Experiments (DOE) as a Strategy for Tuning Lipid Nanoparticle Formulations for RNA Delivery - Publications

Lidia Gurba-Bryśkiewicz, Wioleta Maruszak, Damian A. Smuga, Krzysztof Dubiel, Maciej Wieczorek - publication

wrz 2023 Oncology / FGFR

Fast Claisen condensation reaction optimization in a continuous flow reactor - Publications

Stanisław Michałek, Antoni Powała, Lidia Gurba-Bryśkiewicz, Natalia Piórkowska, Patrycja Olejkowska, Abdellah Yamani, Zbigniew Ochal, Krzysztof Dubiel,  Maciej Wieczorek - publication

lip 2023 Neuropsychiatry

Dual Piperidine-Based Histamine H3 and Sigma-1 Receptor Ligands in the Treatment of Nociceptive and Neuropathic Pain - Publications

Katarzyna Szczepańska, Tadeusz Karcz*, Maria Dichiara, Szczepan Mogilski, Justyna Kalinowska-Tłuścik, Bogusław Pilarski, Arkadiusz Leniak, Wojciech Pietruś, Sabina Podlewska, Katarzyna Popiołek-Barczyk, Laura J. Humphrys, M. Carmen Ruiz-Cantero, David Reiner-Link, Luisa Leitzbach, Dorota Łażewska, Steffen Pockes, Michał Górka, Adam Zmysłowski, Thierry Calmels, Enrique J. Cobos, Agostino Marrazzo, Holger Stark, Andrzej J. Bojarski, Emanuele Amata and Katarzyna Kieć-Kononowicz - publication

kwi 2023 Inflammatory diseases / PI3K

Tuning the Biological Activity of PI3Kδ Inhibitor by the Introduction of a Fluorine Atom Using the Computational Workflow - Publications

Wojciech Pietruś, Mariola Stypik, Marcin Zagozda, Martyna Banach, Lidia Gurba-Bryśkiewicz, Wioleta Maruszak, Arkadiusz Leniak, Rafał Kurczab, Zbigniew Ochal, Krzysztof Dubiel, Maciej Wieczorek

publication

 

kwi 2023 Oncology / FGFR

ESMO TAT 2023 - Publications

mar 2023 Inflammatory diseases / PI3K

Development and optimization of a continuous flow ester reduction with LiAlH4 in the synthesis of a key intermediate for a PI3Kδ inhibitor (CPL302415)† - Publications

Stanisław Michałek, Anna M. Maj, Lidia Gurba-Bryśkiewicz, Wioleta Maruszak, Marcin Zagozda, Zbigniew Ochal, Krzysztof Dubiel and Maciej Wieczorek

publication

lis 2022 Inflammatory diseases / PI3K

The design of experiments (DoE) in optimization of an aerobic flow Pd-catalyzed oxidation of alcohol towards an important aldehyde precursor in the synthesis of phosphatidylinositide 3-kinase inhibitor (CPL302415) - Publications

publication

lis 2022 Neuropsychiatry / PDE10A

A PDE10A inhibitor CPL500036 is a novel agent modulating striatal function devoid of most neuroleptic side-effects - Publications

Mikolaj Matloka, Sylwia Janowska, Piotr Pankiewicz, Sofiya Kokhanovska, Tomasz Kos, Małgorzata Hołuj, Izabela Rutkowska-Wlodarczyk, Krzysztof Abramski, Monika Janicka, Piotr Jakubowski, Maciej Świątkiewicz, Marlena Welniak-Kaminska, Joanna Hucz-Kalitowska, Paulina Dera, Lukasz Bojarski, Paweł Grieb, Piotr Popik ,Maciej Wieczorek, Jerzy Pieczykolan

publication

paź 2022 Inflammatory diseases / JAK/ROCK

Implementation of QbD Approach to the Development of Chromatographic Methods for the Determination of Complete Impurity Profile of Substance on the Preclinical and Clinical Step of Drug Discovery Studies - Publications

Lidia Gurba-Bryskiewicz, Urszula Dawid, Damian A. Smuga, Wioleta Maruszak, Monika Delis,
Krzysztof Szymczak, Bartosz Stypik, Aleksandra Moroz, Aleksandra Błocka, Michał Mroczkiewicz,
Krzysztof Dubiel, Maciej Wieczorek

publication

wrz 2022 Oncology / FGFR

FGFR1–4 RNA-Based Gene Alteration and Expression Analysis in Squamous Non-Small Cell Lung Cancer - Publications

by Joanna Moes-Sosnowska,Monika Skupinska,Urszula Lechowicz,Ewa Szczepulska-Wojcik,Paulina Skronska,Adriana Rozy,Aneta Stepniewska,Renata Langfort,Piotr Rudzinski,Tadeusz Orlowski,Delfina Popiel,Aleksandra Stanczak,Maciej Wieczorek and Joanna Chorostowska-Wynimko

publication

sie 2022 Inflammatory diseases / PI3K

Design, Synthesis, and Development of Pyrazolo[1,5-a]pyrimidine Derivatives as a Novel Series of Selective PI3Kδ Inhibitors: Part II—Benzimidazole Derivatives - Publications

Mariola Stypik,Stanisław Michałek ,Nina Orłowska,Marcin Zagozda,Maciej Dziachan,Martyna Banach,Paweł Turowski,Paweł Gunerka,Daria Zdżalik-Bielecka,Aleksandra Stańczak,Urszula Kędzierska,Krzysztof Mulewski,Damian Smuga,Wioleta Maruszak,Lidia Gurba-Bryśkiewicz,Arkadiusz Leniak,Wojciech Pietruś,Zbigniew Ochal,Mateusz Mach,Beata Zygmunt,Jerzy Pieczykolan,Krzysztof Dubiel, Maciej Wieczorek

publication

sie 2022 Inflammatory diseases

Design, Synthesis, and Development of pyrazolo[1,5-a]pyrimidine Derivatives as a Novel Series of Selective PI3Kδ Inhibitors: Part I—Indole Derivatives - Publications

by Mariola Stypik, Marcin Zagozda, Stanisław Michałek, Barbara Dymek,Daria Zdżalik-Bielecka, Maciej Dziachan, Nina Orłowska, Paweł Gunerka, Paweł Turowski, Joanna Hucz-Kalitowska, Aleksandra Stańczak, Paulina Stańczak, Krzysztof Mulewski , Damian Smuga, Filip Stefaniak, Lidia Gurba-Bryśkiewicz, Arkadiusz Leniak, Zbigniew Ochal, Mateusz Mach, Karolina Dzwonek

publication

maj 2022 Oncology

Two-Front War on Cancer—Targeting TAM Receptors in Solid Tumour Therapy - Publications

Agata Mikolajczyk,Filip Mitula,ORCID,Delfina Popiel,Bozena Kaminska,Maciej Wieczorek and Jerzy Pieczykolan

publication

maj 2022 Oncology

Two-Front War on Cancer—Targeting TAM Receptors in Solid Tumour Therapy - Publications

Agata Mikolajczyk, Filip Mitula, Delfina Popiel, Bozena Kaminska, Maciej Wieczorek, Jerzy Pieczykolan

publication

kwi 2022 Neuropsychiatry / Esketamine

Esketamine inhaled as dry powder : Pharmacokinetic, pharmacodynami can dsafety assessment in a preclinical study - Publications

Mikołaj Matłok, Sylwia Janowska, Anna Gajoss - Draus, Hubert Ziółkowski,Monika Janicka, Przemysław Perko, Kisło Kamila, Piotr Pankiewicza, Rafał Moszczyński-Pętkowski, Mateusz Mach,  Paulina Dera, Krzysztof Abramski, Małgorzata Teska-Kamińska, Ewa Tratkiewicz, Maciej Wieczorek, Jerzy Pieczykolan;

publication

 

 

lis 2021 Oncology / FGFR

p38 Mediates Resistance to FGFR Inhibition in Non-Small Cell Lung Cancer - Publications

Izabela Zarczynska  , Monika Gorska-Arcisz  , Alexander Jorge Cortez  , Katarzyna Aleksandra Kujawa, Agata Małgorzata Wilk, Andrzej Cezary Skladanowski, Aleksandra Stanczak, Monika Skupinska , Maciej Wieczorek, Katarzyna Marta Lisowska  , Rafal Sadej,  Kamila Kitowska

publication

 

lis 2021 Neuropsychiatry

CPL500036 - a novel inhibitor of phosphodiesterase 10A - attenuates parkinsonian-like and L-DOPA induced dyskinetic effects in 6-OHDA lesioned rats - Posters

M. Matłoka, T. Lenda, K. Ossowska, K. Berghauzen-Maciejewska, D. Biała, A. Gajos-Draus, P. Pankiewicz, K. Mulewska, A. Janusz, D. Smuga, M. Górka, J. Pieczykolan, M. Wieczorek, J. Konieczny, Poster at Neuroscience 2021, 50th Annual Meeting 8-11 November

poster 2021

wrz 2021 Diabetes / GPR40

Evaluation of the hepatotoxicity of the novel GPR40 (FFAR1) agonist CPL207280 in the rat and monkey - Publications

Katarzyna Bazydło-Guzenda, Paweł Buda, Mateusz Mach, Jerzy Pieczykolan, Izabela Kozlowska, Michał Janiszewski, Ewa Drzazga, Jakub Dominowski, Hubert Ziolkowski, Maciej Wiezorek, Shayne Cox Gad

publication

 

wrz 2021 Diabetes / GPR40

Discovery and development of CPL207280 as new GPR40/FFA1 agonist - Publications

Mateusz Mach, Katarzyna Bazydło-Guzenda, Paweł Buda, Mikołaj Matłoka, Radosław Dzida, Filip Stelmach, Kinga Gałązka, Małgorzata Wąsińska - Kałwa, Damian Smuga, Dagmara Hołowińska, Urszula Dawid, Lidia Gurba-Bryśkiewicz, Krzysztof Wiśniewski, Krzysztof Dubiel, Jerzy Pieczykolan, Maciej Wieczorek

publication

 

 

wrz 2021 Oncology / FGFR

Analysis of fibroblast growth factor receptor 3 aberrations in bladder cancer, for enabling personalized and effective therapy based on FGFR inhibitor - Posters

R. Sosnowski, D. Popiel, P. Gapska, M. Skupinska, P. Stajno, M. Sobieszek-Prochorec, M. Ligaj, T. Demkow, A. Stanczak, M. Wieczorek, J. Pieczykolan, Poster at European Society for Medical Oncology 16 - 21 Sep 2021 Paris, Virtual, France

poster 2021

wrz 2021 Neuropsychiatry / Esketamine

Safety assessment of esketamine administration via dry powder inhaler in patients with treatment-resistant bipolar depression - Posters

M. Wieczorek, S. Janowska, P. Gałecki, Poster at the 34th ECNP Congress, 2-5 October 2021, Lisbon, Portugal

wrz 2021 Neuropsychiatry / Esketamine

Safety assessment of esketamine administered via dry powder inhaler in patients with treatment-resistant major depression - Posters

S. Janowska, M. Wieczorek, P. Gałecki, Poster at the 34th ECNP Congress, 2-5 October 2021, Lisbon, Portugal

wrz 2021 Neuropsychiatry / Esketamine

Inflammatory cytokine plasma levels correlation with MADRS score in patients with treatment-resistant major depression after dry-powder inhaled esketamine administration - Posters

M. Matłoka, A. Gajos-Draus, I. Majkowska, S. Kokhanovska, P. Pankiewicz, S. Janowska, K. Wójcik, M. Wieczorek, J. Pieczykolan, Poster at the 34th ECNP Congress, 2-5 October 2021, Lisbon, Portugal

poster 2021

wrz 2021 Oncology / FGFR

FGFR1 gene aberrations and FGFR1 protein expression in squamous non-small cell lung cancer (Sq-NSCLC) - Posters

J. Moes-Sosnowska, A. Rozy, M. Skupińska, U. Lechowicz, E. Szczepulska-Wojcik, R. Langfort, P. Rudzinski, T. Orlowski, D. Popiel, M. Wieczorek, A. Stanczak, J. Chorostowska-Wynimko, E-poster European Respiratory Society (ERS) 2021, 5–8 September 2021

wrz 2021 Inflammatory diseases / PI3K

Potent and selective indol-4-YL pyrazolo[1,5-a]pyrimidine-derived PI3Kδ inhibitors as potential candidates for treatment of copd and asthma - Posters

Stanisław Michałek, Mariola Stypik, Marcin Zagozda, Nina Orłowska, Martyna Banach, Urszula Kędzierska, Beata M. Zygmunt, Kamila Gala, Maciej Dziachan, Barbara Dymek, Daria Zdzalik, Paweł Gunerka, Paweł Turowski, Maria Bretner, Zbigniew Ochal, Krzysztof Dubiel, Jerzy Pieczykolan, Maciej Wieczorek

poster_2021

wrz 2021 Inflammatory diseases / JAK/ROCK

Novel benzimidazole-derived PI3Kδ inhibitors as highly potent drugs candidates for SLE and other inflammatory and autoimmune diseases - Posters

Mariola Stypik, Stanisław Michałek, Marcin Zagozda, Nina Orłowska, Martyna Banach, Urszula Kędzierska, Beata M. Zygmunt, Kamila Gala, Maciej Dziachan, Barbara Dymek, Daria Zdzalik, Paweł Gunerka, Paweł Turowski, Zbigniew Ochal, Maria Bretner, Krzysztof Dubiel, Jerzy Pieczykolan, Maciej Wieczorek

poster 2021

 

sie 2021 Neuropsychiatry

Antiparkinsonian - like effects of CPL500036, a novel selective inhibitor of phosphodiesterase 10A, in the unilateral rat model of Parkinson's disease - Publications

Tomasz Lenda, Krystyna Ossowska, Klemencja Berghauzen-Maciejewska, Mikołaj Matłoka, Jerzy Pieczykolan, Maciej Wieczorek, Jolanta Konieczny

publication

sie 2021 Diabetes / GPR40

CPL207280 - a novel GPR40/FFA1 - specific agonist shows a favorable safety profile and exerts anti-diabetic effects in type 2 diabetic animals - Publications

Katarzyna Bazydlo-GuzendaPawel BudaMikolaj MatlokaMateusz MachFilip StelmachRadoslaw DzidaDamian SmugaJoanna Hucz-KalitowskaMalgorzata Teska-KaminskaVarvara VialichkaKrzysztof DubielBozena KaminskaMaciej Wieczorek and Jerzy Pieczykolan.

lip 2021 Neuropsychiatry

Do Small Molecules Activate the TrkB Receptor in the Same Manner as BDNF? Limitations of Published TrkB Low Molecular Agonists and screening for Novel TrkB Od Srthosteric Agonists - Publications

Piotr Pankiewicz, Marcin Szybiński, Katarzyna Kisielewska, Filip Gołębiowski, Patryk Krzemiński, Izabela Rutkowska Włodarczyk, Rafał Moszczyński Pętkowski, Lidia Gurba Bryśkiewicz, Monika Delis, Krzysztof Mulewski, Damian Smuga, Jakub Dominowski, Artur Janusz, Michał Górka, Krzysztof Abramski, Agnieszka Napiórkowska, Marcin Nowotny, Krzysztof Dubiel, Katarzyna Kalita, Maciej Wieczorek, Jerzy Pieczykolan, Mikołaj Matłoka

publication

cze 2021 Diabetes / GPR40

Development and Bio-Predictive Evaluation of Biopharmaceutical Properties of Sustained-Release Tablets with a Novel GPR40 agonist for First-in-Human Clinical Trial - Publications

Ewelina Juszczyk, Kamil Kisło, Paweł ̇Zero, Ewa Tratkiewicz, Maciej Wieczorek, Jadwiga Paszkowska, Grzegorz Banach, Marcela Wiater, Dagmara Hoc, Grzegorz Garbacz, Jaroslaw Sczodrok, Dorota Danielak

publication

kwi 2021 Inflammatory diseases / JAK/ROCK

A novel JAK/ROCK inhibitor, CPL409116, demonstrates potent efficacy in the mouse model of systemic lupus erythematosus - Publications

Maria Dulak-Lis, Anna Bujak, Kamila Gala, Martyna Banach, Urszula Kędzierska, Joanna Miszkiel, Joanna Hucz-Kalitowska, Michał Mroczkiewicz, Bartosz Stypik, Krzysztof Szymczak, Paweł Gunerka, Krzysztof Dubiel, Beata M. Zygmunt, Maciej Wieczorek, Jerzy S. Pieczykolan

publication

kwi 2021 Oncology / FGFR

MET-Pyk2 Axis Mediates Acquired Resistance to FGFR Inhibition in Cancer Cells - Publications

Kitowska K., Gorska-Arcisz M., Antoun D., Zarczynska I., Czaplinska D., Szczepaniak A., Skladanowski C.A., Wieczorek M., Stanczak A., Skupinska M., Sadej R.

publication

sty 2021 Oncology / FGFR

RNA-Based Gene Alteration and Expression Analysis in Sq-NSCLC with known FGFR1 Amplification and Protein Expression Status - Posters

 J. Moes-Sosnowska, A. Rozy, M. Skupinska, U. Lechowicz, E. Szczepulska-Wojcik,1 R. Langfort,  P. Rudzinski,  T. Orlowski,  D. Popiel,  M. Wieczorek,  A. Stańczak, J. Chorostowska-Wynimko, Worldwide Virtual Event IASLC  : World Conference on Lung Cancer 2020 ; January 2021

cze 2020 Oncology / FGFR

Discovery and optimization of novel pyrazole-benzimidazole CPL304110, as a potent and selective inhibitor of fibroblast growth factor receptors FGFR (1-3) - Publications

Yamani A., Zdżalik-Bielecka D., Lipner j., Stańczak A., Piórkowska N., Stańczak P., Olejkowska P., Hucz-Kalitowska J., Magdycz M., Dzwonek K., Dubiel K., Lamparska-Przybysz M., Popiel D., Pieczykolan J., Wieczorek M.

publication

cze 2020 Oncology / FGFR

Preclinical characterization of CPL304110 as a potential selective inhibitor of Fibroblast Growth Factors 1/2/3 in solid cancers - Posters

Popiel D., Mikołajczyk A., Skupińska M., Hucz-Kalitowska J., Stańczak P., Piorkowska N., Yamani A., Dubiel K., Stańczak A., Pieczykolan J., Wieczorek M.

poster 2020

 

cze 2020 Oncology / FGFR

Comparing different methods of FGFR1 aberrations analysis in squamous cell lung cancer (SQCLC) potential targeted therapy - Posters

Skupińska M., Obtułowicz T., Moes-Sosnowska J., Rozy A., Szczepulska- Wójcik E., Langfort R., Chorostowska-Wynimko J., Stańczak A., Pieczykolan J., Wieczorek M., Popiel D.

poster 2020

 

cze 2020 Oncology / FGFR

Molecular profiling of Sq-NSCLC with enhanced FGFR1-4 and MET gene expression - NGS pilot study - Posters

Moes-Sosnowska J., Szczepulska-Wojcik E., Rozy A., Langfort R., Rudzinski P., Orlowski T., Skupinska M., Popiel D., Wieczorek M., Stanczak A., Chorostowska-Wynimko J.

poster 2020

cze 2020 Diabetes / GPR40

Development of SR matrix tablet containing a new GPR40 agonist for first-in human clinical trial - Posters

Ewelina Juszczyk, Kamil Kisło, Paweł Żero, Ewa Tratkiewicz, Jadwiga Paszkowska, Dorota Danielak, Jarosław Szczodrok, Grzegorz Garbacz

poster 2020

cze 2020 Inflammatory diseases / PI3K

Preclinical characterization of CPL302-253, a selective inhibitor of P13K, as the candidate for the inhalatory treatment and prevention of asthma - Publications

mar 2020 Neuropsychiatry / PDE10A

The study of molecular changes induced by CPL500-036, a potential novel anti-dyskinetic drug, in 6-OHDA rat model of PD - Posters

Gajos-Draus A., Mulewski K., Górka M., Konieczny J., Lenda T., Ossowska K., Biala D., Kokhanovska S., Smuga D., Pieczykolan J., Wieczorek M, Matłoka M.
Poster at the 2020 ECNP Workshop on Junior Scientists in Europe, 5-8 March 2020, Nice, France
10.1016/j.euroneuro.2019.12.006

lut 2020 Neuropsychiatry

The study of molecular changes induced by CPL500-036, a potential novel anti-dyskinetic drug, in 6-OHD rat model of PD - Posters

Gajos-Draus A., Mulewski K., Górka M., Konieczny J., Lenda T., Ossowska K., Biala D., Kokhanovska S., Smuga D., Pieczykolan J., Wieczorek M., Matłoka M.

poster 2020

cze 2019 Oncology / FGFR

Efficacy study of Celon Pharma FGFR kinase inhibitor in two patient-derived tumour xenograft (PDTX) models - Posters

Hucz-Kalitowska J., Teska-Kamińska M., Stańczak A., Skupińska M., Mikołajczyk A., Pieczykolan J., Wieczorek M.,

poster 2019

cze 2019 Neuropsychiatry / Esketamine

Safety assessment of esketamine administered via dry powder inhalation in animals and humans during preclinical toxicology and phase I clinical study - Posters

Matłoka M., Janowska J., Sierzputowska J., Jarus-Dziedzic K., Pieczykolan J., Wieczorek M.

poster 2019

cze 2019 Neuropsychiatry / Esketamine

Safety and pharmacokinetic study of inhaled esketamine after a multiple dose in healthy volunteers - Posters

Janowska S., Tratkiewicz E., Matłoka M., Perko P., Gaciarz  M., Wieczorek M.

poster 2019

 

cze 2019 Neuropsychiatry / PDE10A

Safety and pharmacokinetic study of phosphodiesterase 10A inhibitor ( CPPL500036 ) after a single dose in healthy volunteers - Posters

Janowska S., Jarus-Dziedzic K., Sierzputowska J., Matłoka M., Wieczorek M.

poster 2019

paź 2018 Neuropsychiatry / Esketamine

Safety and pharmacokinetics study of inhaled esketamine after a single dose in healthy volunteers - Posters

Janowska S., Tratkiewicz E., Matłoka M., Perko P., Gaciarz M., Wieczorek M.

poster 2018

paź 2018 Diabetes / GPR40

Novel GPR40 agonist CPL-207-280 independently improves glycaemia and mitigates neuropathic pain in diabetic rodents - Posters

Paweł Buda, Katarzyna Bazydło-Guzenda, Mateusz Mach, Filip Stelmach, Radosław Dzida, Joanna Hucz-Kalitowska, Małgorzata Teska-Kaminska, Krzysztof Dubiel, Jerzy Pieczykolan, Maciej Wieczorek

poster 2018

paź 2018 Neuropsychiatry / PDE10A

Novel and highly bioavailable PDE10A inhibitor activates cyclic nucleotides depending signaling in rat striatum - Posters

Pankiewicz P., Janowska S., Gajos-Draus A., Mozolewski P., Drzazga E., Kokhanovska S., Janicka M., Hucz-Kalitowska J., Świątkieicz M., Wełniak-Kamińska M., Fiedorowicz M., Grieb P., Pieczykolan J., Wieczorek M., Matłoka M.

poster 2018

 

wrz 2018 Neuropsychiatry / Esketamine

pharmacodynamics-of-s-ketamine-and-ketamine-racemate-in-rat-pfc-and-hp-after-dry-powder-inhalation-intratracheal-and-intravenous-administration - Posters

Ketamine High Dose Dry Powder Composition for Pulmonary Administration, Gajos-Draus A., Janowska S., Janicka M., Wieczorek M., Pieczykolan J., Matloka M.
Poster at 31st ECNP 2018, 6-9 September 2018, Barcelona, Spain.

wrz 2018 Neuropsychiatry / PDE10A

cpl-500-036-02-novel-and-highly-bioavailable-pde10a-inhibitor-activates-cyclic-nucleotides-depending-signaling-in-rat-striatum - Posters

Pankiewicz P., Janowska S., Gajos-Draus A., Mozolewski P., Drzazga E., Janicka M., Hucz-Kalitowska J., Świątkiewicz M., Wełniak-Kamińska M., Fiedorowicz M. Grieb P., Pieczykolan J., Wieczorek M., Matłoka M.
Poster at the 31st ECNP 2018, 6-9 September 2018, Barcelona, Spain.
https://doi.org/10.1016/j.euroneuro.2018.11.798

wrz 2018 Neuropsychiatry / Esketamine

safety-and-pharmacokinetics-study-of-inhaled-esketamine-after-a-single-dose-in-healthy-volunteers - Posters

Janowska, S., Tratkiewicz, E., Matloka, M., Perko, P., Gaciarz, M., Urban, A., Wieczorek, M.
Poster at 31st ECNP 2018, 6-9 September 2018, Barcelona, Spain.

lip 2018 Neuropsychiatry / 5-HT6R

Pyrroloquinoline scaffold-based 5-HT6R ligands: synthesis, quantum chemical and molecular dynamic studies, and influence of nitrogen atom position in thescaffold on affinity - Publications

Grychowska, Rafał Kurczab, Paweł Śliwa, Grzegorz Satała, Krzysztof Dubiel, Mikołaj Matłoka, Rafał Moszczyński-Pętkowski, Jerzy Pieczykolan, Andrzej J. Bojarski, Paweł Zajdel Bioorganic & Medicinal Chemistry Volume 26, Issue 12, 23 July 2018, Pages 3588-3595 doi: 10.1016/j.bmc.2018.05.033

lip 2018 Oncology / FGFR

The role of FGFR2 amplification and expression in patients with advanced or metastatic gastric cancer receiving fluoropyrimidine - based chemotherapy - Posters

Skupińska M., Jesiotr M., Chrom P., Mróz A., Cierniak S., Winiarek M., Wyrwicz L., Pieczykolan J., Wieczorek M., Stańczak A., Bodnar L.

poster 2018

cze 2018 Oncology

Rational-based drug design of novel, highly potent MER inhibitors as potential treatment of cancers - Posters

Mikolajczyk A., Yamani A., Olejkowska P., Piorkowska N., Naitana M., Maliszewski P., Dubiel K., Pieczykolan J., wieczorek M., Stanczak A.

poster 2018

cze 2018 Oncology

CPL-410-005, a novel ubiquitin-activating enzyme (UAE) inhibitor in preclinical evaluation as ananticancer treatment for solid tumours - Posters

Kozłowska D., Górnicka A., Stypik B., Mroczkiewicz M., Mikolajczyk A., Hucz-Kalitowska J.,Szwalbe A., Mulewski K., Smuga D., Dubiel K., Pieczykolan J., Wieczorek M., Stańczak A.

poster 2018

 

cze 2018 Oncology / FGFR

Analiza mutacji FGFR3 w grupie 116 pacjentów z niezaawansowaną postacią raka pęcherza moczowego - Posters

Gapska P., Sosnowski R., Stajno P., Ligaj M., Prochorec-Sobieszek M., Pieczykolan J., Wieczorek M., Demkow T., Stańczak A.

poster 2018

 

cze 2018 Oncology / FGFR

Search for predictive biomarkers of sensitivity/resistance against novel FGFR inhibitor using array-based comparative genomic hybridization(aCGH) and RNA sequencing (RNAseq)-preliminary results - Posters

Cortez A.J., Kujawa K.A., Tudrej P.A., Kitowska K., Sądej R., Student S., Klyszcz K., Lisowska K.M.

poster 2018

cze 2018 Neuropsychiatry / Esketamine

Pyrroloquinoline scaffold-based 5-HT6R ligands: synthesis, quantum chemical and molecular dynamic studies and influence of nitrogen atom position in thescaffold on affinity - Publications

Bioorganic & Medicinal Chemistry doi: 10.1016/j.bmc.2018.05.033,

cze 2018 Neuropsychiatry / Esketamine

LC-MS/MS chiral method for simultaneous determination of RS-ketamine and its metabolites in rat plasma and brain samples frpm pharmacokinetic studies - Posters

Janicka M., Matłoka M., Mach M., Moszczyński-Pętkowski R., Pieczykolan J., Tratkiewicz E., Wieczorek M.

poster 2018

cze 2018 Neuropsychiatry / Esketamine

Pharmacokinetic properties of S-ketamine and ketamine racemate after dry powder inhalation, intravenous and intratracheal administration in rats - Posters

Matłoka M., Janowska S., Janicka M., Mach M., Moszczyński-Pętkowski R., Ziółkowski H., Draus A., Tratkiewicz E., Pieczykolan J., Wieczorek M.

poster 2018

cze 2018 Neuropsychiatry / Esketamine

Pharmacodynamics of S-ketamine and ketamine racemate in rat PFC and HP after dry powder inhalation, intratracheal nd intravenous administration - Posters

Gajos- Draus A., Janowska S., Janicka M., Wieczorek M., Pieczykolan J., Matłoka M.

poster 2018

cze 2018 Diabetes / GPR40

Discovery of CPL 207-280CA, an effective and safe GPR40 agonist for the treatment of type 2 diabetes - Posters

Katarzyna Bazydło, Paweł Buda, Mateusz Mach, Radosław Dzida, Filip Stelmach, Krzysztof Dubiel, Jerzy Pieczykolan, Maciej Wieczorek

 poster 2018

maj 2018 Neuropsychiatry / PDE10A

Synthesis and characterization of novel classes of PDE10A inhibitors - 1H - 1,3-benzodiazoles and imidazo [1,2-a] pyrimidines - Publications

Rafał Moszczyński-Pętkowski, Jakub Majer, Małgorzata Borkowska, Łukasz Bojarski, Sylwia Janowska, Mikołaj Matłoka, Filip Stefaniak, Damian Smuga, Katarzyna Bazydło, Krzysztof Dubiel, Maciej Wieczorek, European Journal of Medicinal Chemistry

publication

maj 2018 Neuropsychiatry / Esketamine

Pharmacokinetic properties of S-ketamine and ketamine racemate after dry powder inhalation, intravenous and intratracheal administration in rats - Posters

Matłoka M., Janowska S., Janicka M., Mach M., Moszczyński-Pętkowski R., Ziółkowski H., Draus A., Tratkiewicz E., Pieczykolan J., Wieczorek M.
Poster at the 2018 APA Annual Meeting, 5-9 May 2018, New York City, USA.

cze 2017 Oncology

Design and development of potent E1 ubiquitin activating enzyme inhibitor, CPL-410-005, as novel anticancer therapy - Posters

Stańczak A., Górnicka A., Stypik B., Mroczkiewicz M., Pieczykolan J., Dubiel K., Wieczorek M.

poster 2017

cze 2017 Oncology / FGFR

Low consistency between FGFR1 gene amplification and protein expression in squamous cell lung cancer (SQCLC) - Posters

Chorostowska-Wynimko J., Skupinska M.M., Rozy A., Siewiera K., Szczepulska E., Langfort R., Rudzinski P., Orlowski T., Wieczorek M., Stanczak A.

poster 2017

cze 2017 Oncology / FGFR

Ovarian cancer cells show enhanced response to the novel FGFR inhibitor CPL-304-110 - Posters

Kujawa K.A., Rusin A. Olbryt M., Tudrej P., Cortez A.J., Stanczak A., Wieczorek M., Lisowska K.M.

poster 2017

cze 2016 Neuropsychiatry

The modulation of cyclic nucleotide dependent pathways in the rat striatum by CPL-500-036-02 - a phosphodiesterase 10A inhibitor - Posters

Sylwia Janowska, Piotr Pankiewicz, Maciej Świątkiewicz, Marlena Wełniak-Kamińska, Małgorzata Borkowska, Jakub Majer, Rafał Moszczyński-Pętkowki, Krzysztof Dubiel, Maciej Wieczorek, Mikołaj Matłoka

poster 2016

maj 2016 Neuropsychiatry / PDE10A

Development of the novel and selective inhibitor of phosphodiesterase 10A-CPL-500-036-02 and exploring its mode of action - Posters

Mikołaj Matłoka, Katarzyna Bieganska, Sylwia Janowska, Piotr Pankiewicz, Katarzyna Kalita, Jerzy Pieczykolan, Leszek Kaczmarek, Maciej Wieczorek

poster 2016

kwi 2016 Neuropsychiatry / PDE10A

The modulation of cyclicnucleotide dependent pathways in the rat striatum by CPL-500-036-02 - a phosphodiesterase 10a inhibitor. - Publications

Janowska S, Pankiewicz P, Swiatkiewicz M, Welniak-Kaminska M, Borkowska M, Majer J, Moszczynski-Petkowski R, Dubiel K, Wieczorek M, Matloka M.
Poster at the 5th Schizophrenia International Research Society Conference, 2 – 6 April 2016, Florence, Italy

paź 2015 Inflammatory diseases / JAK/ROCK

Differences in gene expression and alterations in cell cycle of acute myeloid leukemia cell lines after treatment with JAK inhibitors - Publications

Pawel Gunerka;  Barbara Dymek; Aleksandra Stanczak; Anna Bujak; Paulina Grygielewicz; Pawel Turowski; Karolina Dzwonek; Monika Lamparska-Przybysz; Tadeusz Pietrucha; Maciej Wieczorek, European Journal of Pharmacology Volume 765, 15 October 2015, Pages 188–197 doi:10.1016/j.ejphar.2015.08.037

sie 2015 Inflammatory diseases / JAK/ROCK

Differences in gene expression and alterations in cell cycle of acute myeloid leukemia cell lines after treatment with JAK inhibitors - Publications

Paweł  Gunerka, Barbara Dymek, Aleksandra Stanczak, Anna Bujak, Paulina Grygielewicz, Paweł Turowski, Karolina Dzwonek, Monika Lamparska-Przybysz, Tadeusz Pietrucha, Maciej Wieczorek, European Journal of Pharmacology 2015, doi:10.1016/j.ejphar.2015.08.037

publication

cze 2015 Oncology / FGFR

Analysis of the intra-tumor heterogeneity and consistency between FGFR1 gene amplification and protein expression in squamous cell lung cancer - Posters

Skupinska M., Jagus P., Grygielewicz P., Mikolajczyk A., Szczepulska E., Rozy A., Langfort R., Chorostowska-Wynimko J., Wieczorek M., Stanczak A.

poster 2015

 

cze 2015 Oncology / FGFR

Preclinical evaluation of a novel, selective pan-FGFR kinase inhibitor CPL-304-110 as a potential anticancer targeted therapy - Posters

Grygielewicz P., PiorkowskaN., Mikołajczyk A., Hucz-Kalitowska J.,Yamani A., Dubiel K., Wiecorek M., stanczak A.

poster 2015

maj 2015 Inflammatory diseases / JAK/ROCK

Highly active and selective JAK2 inhibitor CPL-407-220 as a new drug candidate for myeloproliferative disorders - Posters

Anna Bujak, Paweł Gunerka1, Joanna Lipner, Michał Mroczkiewicz, Bartosz Stypik, Paweł Turowski, Maciej Wieczorek

Posters 1.InnovativeDrugsR&DDepartment, Celon Pharma S.A., Lomianki, Poland; 2. Postgraduate School of Molecular Medicine, Warsaw Medical University,Poland; 3.Department of Medical Biotechnology, Medical University of Lodz, Poland

poster 2015

kwi 2015 Inflammatory diseases / JAK/ROCK

Novel, highly potent and selective JAK3 inhibitor CPL-409-057 disrupting IL-4/IL-13 signaling in asthma therapy - Posters

Anna Bujak, Paweł Gunerka, Joanna Lipner, Michał Mroczkiewicz, Bartosz Stypik, Paweł Turowski, Maciej Wieczorek

Poster 1.Celon Pharma S.A., Lomianki; 2. Postgraduate School of Molecular Medicine, Warsaw Medical University; 3. Department of Medical Biotechnology, Medical University of Lodz, Poland

poster 2015

 

mar 2015 Inflammatory diseases / PI3K

Pharmacokinetics of selective P13K inhibitors after intratracheal instillation in mice - Posters

Pawel Turowski, Paweł Gunerka, , Joanna Hucz-Kalitowska, Marcin Zagozda, Maciej Dziachan, Mariola Sekular, Anna Bujak,Maciej Wieczorek

Poster 11Innovative DrugsR&DDepartment, Celon Pharma S.A., Kielpin, Lomianki, Poland 2Postgraduate Schoolof MolecularMedicine, Warsaw Medical University, Warsaw,Poland 3Department of Medical Biotechnology, Medical University of Lodz, Lodz, Poland

poster 2015

lis 2014 Oncology / FGFR

Epithelial-mesenchymal transition confers resistance to selective FGFR inhibitors in SNU-16 gastric cancer cells, - Publications

Grygielewicz P1, Dymek B, Bujak A, Gunerka P, Stanczak A, Lamparska-Przybysz M, Wieczorek M, Dzwonek K, Zdzalik D, Gastric Cancer 2014 Nov 19

kwi 2014 Oncology

Activating mutations in ALK kinase domain confer resistance to structurally unrelated ALK inhibitors in NPM-ALK-positive anaplastic large-cell lymphoma. - Publications

Zdzalik D, Dymek B, Grygielewicz P, Gunerka P, Bujak A, Lamparska-Przybysz M, Wieczorek M, Dzwonek K., J Cancer Res Clin Oncol. 2014 Apr;140(4):589-98

lut 2014 Oncology

Wnt/β-catenin pathway as a potential prognostic and predictive marker in patients with advanced ovarian cancer - Publications

Bodnar L, Stanczak A, Cierniak S, Smoter M, Cichowicz M, Kozlowski W, Szczylik C, Wieczorek M, Lamparska-Przybysz M. J, Ovarian Res. 2014 Feb 6;7:16.

gru 2011 Oncology

Prognostic significance of Wnt-1, ß-catenin and E-cadherin expression in advanced colorectal carcinoma - Publications

Stanczak A, Stec R, Bodnar L, Olszewski W, Cichowicz M, Kozlowski W, Szczylik C, Pietrucha T, Wieczorek M, Lamparska-Przybysz M, Pathol Oncol Res. 2011 Dec;17(4):955-63.

gru 2010 Neuropsychiatry / PDE10A

In vitro findings of alterations in intracellular calcium homeostasis in schizophrenia - Publications

Bojarski L, Debowska K, Wojda U., Prog Neuropsychopharmacol Biol Psychiatry. 2010 Dec 1;34(8):1367-74.

lip 2008 Oncology

Silencing of Wnt-1 by siRNA induces apoptosis of MCF-7 human breast cancer cells - Publications

Wieczorek M, Paczkowska A, Guzenda P, Majorek M, Bednarek AK, Lamparska-Przybysz M. . Cancer Biol Ther. 2008 Feb;7(2):268-74.